Sanofi Profit Growth Beats Market View on Early Start of Vaccine Sales
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials for next-generation drugs. CEO Paul Hudson's spending plans were initially met with a massive stock market slump a year ago but the shares have rebounded.
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.Most Read from BloombergRobotaxis Are No Friend of Public TransportationBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiArgentina Drug Trafficking Hotspot Sees Murders PlungeClimate Change Is Killing Buildings in Slow MotionEarnings per share excluding some items reached €2.
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
Sanofi reaches deal on terms of sale of consumer health arm, say French government sources
Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private ...
Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend
Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice ...
FiercePharma1h
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Sanofi in Exclusive Talks With CD&R Over Sale of $17 Billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
Sanofi workers in France to strike over sale of consumer health unit, union official says
France's CGT and CFDT unions have called on workers at pharma company Sanofi to strike from Thursday to show their protest ...
FiercePharma4d
Sanofi in 'exclusive negotiations' to sell 50% stake in €16B consumer health unit Opella
Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to ...
CD&R Faces Tough Road to 20% Returns With Sanofi
The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than ...
BioPharma Dive3d
Sanofi moves ahead with CD&R deal for stake in consumer business
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...
Drug Store News4d
Sanofi, CD&R partner to support Opella’s growth in consumer health care
Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.